Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Item

http://www.wikidata.org/entity/Q54594739

Q54594739

about

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists Discovery of new molecular subtypes in oesophageal adenocarcinoma HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.Her2/neu testing in gastric cancer: evaluating the risk of sampling errors Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Novel diagnostic and prognostic biomarkers in esophageal cancer.Advances in biomarkers for esophageal cancer.HER2 assessment by silver in situ hybridization: where are we now?Genomics of Esophageal Cancer and Biomarkers for Early Detection.Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus.The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.Early HER2 dysregulation in gastric and oesophageal carcinogenesis A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

P2860

Q28078111-28A96180-F534-4585-977B-68D135B6B3E7 Q28744610-F03FA060-3780-4707-B764-ADCC9EE4D084 Q33690070-E4AF9DCC-B596-4C8A-AFF7-A7FF57AB18AB Q34852929-B62D9168-4A38-4D2E-A383-697276C2FAD4 Q35140953-AA3A40B5-0228-499C-92E3-CB69B4D35B58 Q35525379-4EF5ED7F-622D-4FDD-B97D-76D4B40E78AE Q35681702-1A332D7C-3A5B-4FEA-8872-2CD6D6F29BAA Q36140927-96C91635-408F-447F-B189-CF32D3FCBFC6 Q36429835-A5E41926-8219-41FC-A87C-80F048118A3B Q36615782-F866632A-0022-4589-82FF-BCD67CAE89F3 Q36910400-ACE71F9A-F34E-435E-BCD1-61C60AFAFB67 Q37522215-EF267D18-C332-43E6-A038-D5D2ACA4FCBF Q38030442-9039D402-4E93-4E97-9CBE-805B719C1DAA Q38149245-9C102B04-3342-4EC1-B56F-BC0733357F6E Q38153443-62DADBFC-A5F2-4578-AA50-73BF2F7F717D Q38314355-5674122F-CD35-4299-B767-E7F5544A388A Q38940530-834B9541-3DF4-451C-8756-00637AD3BD90 Q42936269-05FEA4BB-3405-4A30-BBF1-FEC806C43461 Q43500705-704B0557-1CF4-4FA3-959D-396E72FC030B Q53657591-80BAC607-6E3D-42DB-AAD7-CB7ADA622583 Q54501808-30274797-D612-4B5A-AEB7-56541E4685D8 Q58003579-B785DE10-563B-4751-8B3D-B05DF11C9F6B Q58763391-C2B72FF4-C5BD-4F6C-A135-76447464D12E

P2860

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Item

http://www.wikidata.org/entity/Q54594739

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@en

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@nl

type

Item

label

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@en

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@nl

prefLabel

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@en

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@nl

P1476

Assessment of ErbB2 (Her2) in ...... escence in situ hybridisation.

@en

P2093

Annette Feuchtinger

http://www.w3.org/2001/XMLSchema#string

Axel Walch

http://www.w3.org/2001/XMLSchema#string

Heinz Höfler

http://www.w3.org/2001/XMLSchema#string

Jörg M Nährig

http://www.w3.org/2001/XMLSchema#string

Marcus Feith

http://www.w3.org/2001/XMLSchema#string

Sandra Rauser

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.

Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P2888

modpathol.2011.52

P304

908-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2011.52

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Helmut Friess

Rupert Langer

P577

2011-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51073106

http://www.w3.org/2001/XMLSchema#string

P698

21516080

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

immunohistochemistry

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

about

P2860

P2860

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921